A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T)

Abu Dhabi Health Services Company

Agios Pharmaceuticals, Inc.
Burjeel Medical City

Project: Clinical Trial

Description

The primary purpose of this study is to compare the effect of mitapivat versus placebo on transfusion burden in participants with transfusion-dependent alpha- or beta-thalassemia (TDT).

Layman's description

The mitapivat group will include approximately 160 participants. The placebo group will include approximately 80 participants.

Acronym	ENERGIZE-T
Status	Active
Effective start/end date	30/11/21 → 30/06/29

Collaborative partners

Agios Pharmaceuticals, Inc. (lead)
Burjeel Medical City
Abu Dhabi Health Services Company

Keywords

Hemolytic Anemia
Congenital Hemolytic Anemia
Anemia
Hematologic Diseases
Hemoglobinopathies
Inborn Genetic Diseases
Thalassemia
beta-Thalassemia
alpha-Thalassemia
Enzyme Activators
Molecular Mechanisms of Pharmacological Action
Mitapivat

Access Project

https://clinicaltrials.gov/study/NCT04770779